ClinicalTrials.gg
CompletedNCT04392219Updated Jul 19, 2021Results posted

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

A Phase 1 interventional study of EIDD-2801 and Placebo in Coronavirus, sponsored by Ridgeback Biotherapeutics, LP. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by Ridgeback Biotherapeutics, LP · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Coronavirus Infections with a site in United Kingdom — 2 open to participants now, 3 under way, 1 of them phase 3. Coronavirus Infections · United Kingdom.

Enrollment
32nd of 44
130 · median 360
Started
2020
with 51 others
Phase 1
7 of 69
none open now
Registered
18th of 69
by date

Among the 69 studies in Coronavirus Infections with a site in United Kingdom, this one is the 32nd largest by enrollment of the 44 interventional ones that give a count, is one of 52 that started in 2020, is one of 7 in phase 1, and was the 18th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

2 of the 69 studies in Coronavirus Infections with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Coronavirus Infections with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, First-in-Human study designed to evaluate the safety, tolerability, and pharmacokinetics of EIDD-2801 following oral administration to healthy volunteers.

03

Conditions studied

  • Coronavirus

Keywords

  • Coronavirus
  • EIDD-2801
  • ribonucleoside
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 18 and 60, inclusive.
  • Female participants must be of non-.
  • Male participants must agree to the use of effective for study duration
  • Is in generally good health as determined by medical history, physical examinations (PEs) (at Screening and/or Check-in), vital signs, and other screening procedures.
  • Has a (BMI) of 18 to 30 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, planning to become pregnant, or breastfeeding.
  • Has a acute or chronic medical condition or disease of the cardiovascular, gastrointestinal (GI), hepatic, renal, endocrine, pulmonary, neurologic, or dermatologic systems as determined by the principal investigator (PI) (or designee).
  • Has any current or historical disease or disorder of the hematological system or significant liver disease or family history of bleeding/ disorders.
  • Has a history of cancer (other than basal cell or squamous cell cancer of the skin), rheumatologic disease or blood dyscrasias.
  • Has a history of gastrointestinal (GI) surgery or other condition that may interfere with absorption of study drug, in the opinion of the principal investigator (PI) (or designee).
  • Has a history of febrile illness within the 14 days prior to the first dose of study drug.
  • Has a positive alcohol or drug screen at Screening or the Day -1 visit or has a history of alcohol or drug abuse within the past 5 years.
  • Currently uses tobacco, nicotine or tobacco products or e-cigarettes, or stopped using tobacco products within the past 3 months
  • Has a total white cell count or absolute lymphocyte count outside the normal range, or or platelet levels below the lower limit of normal, at Screening or Day -1.
  • Has values above the for the following laboratory analytes: /serum glutamic pyruvic transaminase (ALT/SGPT), alkaline phosphatase (serum), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), at Screening or Day -1.
  • Positive test result for (HIV), virus (HBV), or virus (HCV).
  • Has an disease, is or is in any way immunocompromised.
  • Has any of the following:

    • corrected for heart rate (using Fridericia's formula) (QTcF) >450 ms confirmed by repeat measurement
    • QRS duration >110 ms confirmed by repeat measurement
    • PR interval >220 ms confirmed by repeat measurements
    • findings which would make QTc measurements difficult or QTc data uninterpretable
    • history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome).
  • Except as noted, has used prescription drugs (other than hormone replacement therapy) within 14 days prior to the first dose of study drug unless, in the opinion of the PI (or designee), the drug will not interfere with study assessments.
  • Has received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 3 months prior to the first dose of study drug and agrees not to receive another experimental agent during the duration of this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    EIDD-2801

    EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.

    Drug: EIDD-2801

  • Placebo comparator
    Placebo

    Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).

    Drug: Placebo

Interventions

  • Part 1: Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo. Part 2: Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner. Part 3: Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.

    Also known as: Molnupiravir

  • DrugPlacebo

    Part 1: Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo. Part 3: Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events

    Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following a single dose of EIDD-2801 in Part 1

    Time frame: From screening through study completion, up to 15 days

  2. Part 3: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events

    Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following multiple doses of EIDD-2801 in Part 3

    Time frame: From screening through study completion, up to 20 days

07

Results

Posted Jul 19, 2021

Participant flow

Participant flow — Overall Study
MilestonePart 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801Part 2 - 200 mg EIDD-2801 (Fasted/Fed)Part 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801
Started166666666610146666666
Completed166666666610146666666
Not completed000000000000000000

Outcome measures

PrimaryPart 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events

Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following a single dose of EIDD-2801 in Part 1

Time frame:
From screening through study completion, up to 15 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events
ParticipantsPart 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801
TEAEs (Overall)720334212
Mild (Grade 1)720334212
Moderate (Grade 2)100010000
Severe (Grade 3)000000000
PrimaryPart 3: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events

Number of participants with treatment emergent adverse events (TEAEs) and severity of TEAEs following multiple doses of EIDD-2801 in Part 3

Time frame:
From screening through study completion, up to 20 days
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events
ParticipantsPart 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801
TEAEs (Overall)72332323
Mild (Grade 1)72332323
Moderate (Grade 2)00010000
Severe (Grade 3)00000000

Adverse events

Collected over From the time of the first study drug administration until the completion of the End of Study visit (Part 1: approximately 15 days, Part 2: approximately 30 days, and Part 3: approximately 20 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - Placebo0/16 (0%)0/16 (0%)7/16 (43.8%)
Part 1 - 50 mg EIDD-28010/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1 - 100 mg EIDD-28010/6 (0%)0/6 (0%)0/6 (0%)
Part 1 - 200 mg EIDD-28010/6 (0%)0/6 (0%)3/6 (50%)
Part 1 - 400 mg EIDD-28010/6 (0%)0/6 (0%)3/6 (50%)
Part 1 - 600 mg EIDD-28010/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1 - 800 mg EIDD-28010/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1 - 1200 mg EIDD-28010/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 - 1600 mg EIDD-28010/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2 - 200 mg EIDD-2801 (Fasted)0/10 (0%)0/10 (0%)2/10 (20%)
Part 2 - 200 mg EIDD-2801 (Fed)0/10 (0%)0/10 (0%)1/10 (10%)
Part 3 - Placebo0/14 (0%)0/14 (0%)7/14 (50%)
Part 3 - 50 mg EIDD-28010/6 (0%)0/6 (0%)2/6 (33.3%)
Part 3 - 100 mg EIDD-28010/6 (0%)0/6 (0%)3/6 (50%)
Part 3 - 200 mg EIDD-28010/6 (0%)0/6 (0%)3/6 (50%)
Part 3 - 300 mg EIDD-28010/6 (0%)0/6 (0%)2/6 (33.3%)
Part 3 - 400 mg EIDD-28010/6 (0%)0/6 (0%)3/6 (50%)
Part 3 - 600 mg EIDD-28010/6 (0%)0/6 (0%)2/6 (33.3%)
Part 3 - 800 mg EIDD-28010/6 (0%)0/6 (0%)3/6 (50%)
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPart 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801Part 2 - 200 mg EIDD-2801 (Fasted)Part 2 - 200 mg EIDD-2801 (Fed)Part 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801
HeadacheNervous system disorders3/161/60/60/61/63/61/60/60/60/100/100/140/61/60/62/60/60/60/6
Feeling hotGeneral disorders0/160/60/60/62/60/60/60/60/60/100/100/140/60/60/60/60/60/60/6
Back painMusculoskeletal and connective tissue disorders0/160/60/60/60/61/61/60/60/60/100/100/140/62/60/61/60/60/60/6
LymphadenopathyBlood and lymphatic system disorders0/160/60/60/60/60/60/60/61/60/100/100/140/60/60/60/60/60/60/6
Ear painEar and labyrinth disorders0/160/60/60/60/60/61/60/60/60/100/100/140/60/60/60/60/60/60/6
TinnitusEar and labyrinth disorders0/160/60/60/60/60/60/60/61/60/100/100/140/60/60/60/60/60/60/6
Abnormal sensation in eyeEye disorders0/160/60/60/60/60/60/60/60/60/100/100/140/60/61/60/60/60/60/6
Eye irritationEye disorders0/161/60/60/60/60/60/60/60/60/100/100/140/60/60/60/60/60/60/6
Abdominal painGastrointestinal disorders0/160/60/61/60/60/60/60/60/60/100/100/140/60/60/60/60/60/60/6
Abdominal pain upperGastrointestinal disorders0/160/60/60/60/60/60/60/60/60/100/100/141/60/60/60/60/60/60/6

Baseline characteristics

Safety population

Age, Continuous
Age, Continuous(years)Part 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801Part 2 - 200 mg EIDD-2801 (Fasted/Fed)Part 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801Total
Mean39.4 (22 to 56)52.0 (34 to 57)41.2 (23 to 58)39.8 (26 to 60)42.0 (23 to 57)38.2 (21 to 57)39.5 (23 to 56)34.2 (24 to 56)30.8 (25 to 46)45.3 (30 to 60)37.5 (19 to 59)34.0 (23 to 56)45.5 (20 to 58)36.8 (22 to 60)36.2 (20 to 58)38.8 (20 to 60)30.8 (20 to 54)30.8 (20 to 58)38.7 (19 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801Part 2 - 200 mg EIDD-2801 (Fasted/Fed)Part 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801Total
Female22212200032110210021
Male14445446667125564566109
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801Part 2 - 200 mg EIDD-2801 (Fasted/Fed)Part 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801Total
American Indian or Alaska Native0000000000000000000
Asian0000000000000000000
Native Hawaiian or Other Pacific Islander0000000000000000000
Black or African American0000101010000010004
White16666565659136655665122
More than one race0000000001100100014
Unknown or Not Reported0000000000000000000
Body mass index
Body mass index(kg/m^2)Part 1 - PlaceboPart 1 - 50 mg EIDD-2801Part 1 - 100 mg EIDD-2801Part 1 - 200 mg EIDD-2801Part 1 - 400 mg EIDD-2801Part 1 - 600 mg EIDD-2801Part 1 - 800 mg EIDD-2801Part 1 - 1200 mg EIDD-2801Part 1 - 1600 mg EIDD-2801Part 2 - 200 mg EIDD-2801 (Fasted/Fed)Part 3 - PlaceboPart 3 - 50 mg EIDD-2801Part 3 - 100 mg EIDD-2801Part 3 - 200 mg EIDD-2801Part 3 - 300 mg EIDD-2801Part 3 - 400 mg EIDD-2801Part 3 - 600 mg EIDD-2801Part 3 - 800 mg EIDD-2801Total
Mean24.80 ± 2.21726.07 ± 2.64923.50 ± 3.50126.68 ± 2.32024.48 ± 2.34925.32 ± 1.84726.45 ± 2.74525.15 ± 1.62323.37 ± 2.95425.38 ± 2.18524.79 ± 2.68122.27 ± 3.37124.97 ± 4.16225.50 ± 3.11724.48 ± 1.90124.32 ± 2.86624.50 ± 3.67924.20 ± 2.50424.81 ± 2.707
08

Study locations

1 site
  • Covance Leeds Clinical Research Unit
    Leeds, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Aug 2020, 4 months.

Results were first posted in Jul 2021, 11 months after primary completion.

Of 35 industry-sponsored phase 1 interventional studies under Coronavirus Infections, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 61 studies reached it within 10 months; a quarter within 3 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2020
First posted
May 18, 2020
StartActual
Apr 10, 2020
Primary completionActual
Aug 11, 2020
CompletionActual
Aug 11, 2020
Results first posted
Jul 19, 2021
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04392219
Lead sponsor
Ridgeback Biotherapeutics, LP
Responsible party
Sponsor
First posted
May 18, 2020
Start date
Apr 10, 2020
Primary completion
Aug 11, 2020
Completion
Aug 11, 2020
Results posted
Jul 19, 2021
Last update
Jul 19, 2021

Study contacts

Jim Bush, MBChB, PhD
principal investigator · Covance Clinical Research Unit Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion